Our Take
Signos is betting that glucose awareness alone drives behavior change—but the company has no published data showing users actually keep weight off after stopping GLP-1s, which is the entire premise.
Why it matters
GLP-1 adoption has exploded, but most users regain weight when they stop. Signos sees an opening to build a behavioral layer on top of Dexcom's newly-cleared over-the-counter CGM. Employers, not insurers, are funding this bet.
Do this week
Benefits teams: audit whether your self-insured plan covers Signos ($129–$449/month subscriptions) as a GLP-1 offset before your next renewal cycle, since employer adoption is Signos' stated growth lever.
Signos lands $20M to build GLP-1 behavior coaching
Signos closed a $20 million Series B funding round led by Dexcom, Blue Cross Blue Shield of Alabama, and Google Ventures (GV). The round brings total funding to $57 million since the company's founding in 2018.
The company combines Dexcom's Stelo sensor—the first over-the-counter continuous glucose monitor cleared by the FDA in 2024—with an app and human coaching program. Signos analyzes glucose data and generates personalized diet and lifestyle recommendations. Subscriptions range from $129 to $449 per month depending on commitment length.
Signos is the only FDA-cleared CGM system marketed for weight management, a regulatory positioning that allows the company to integrate glucose data into a single user-facing platform and operate it as a medical device rather than a consumer app.
The GLP-1 rebound problem is real; Signos' solution is unproven
Signos CEO Sharam Fouladgar-Mercer frames the problem sharply: GLP-1 drugs suppress appetite but do not teach metabolic awareness. When users stop, they revert to old eating patterns because they never understood how their body responds to food. Over 115 million U.S. adults have prediabetes (per company statement), yet 80% are unaware of the condition.
The company's thesis is that real-time glucose feedback, paired with AI-generated insights about how food, meal timing, movement, and stress affect metabolism, can create lasting behavior change. Investors appear convinced that this layer is missing from the GLP-1 ecosystem.
What remains absent: published data showing that Signos users actually maintain weight loss after stopping GLP-1s or other weight loss interventions. The company has no independent benchmark or peer-reviewed trial demonstrating that glucose awareness alone sustains behavior change in the long term. Fouladgar-Mercer's observation about GLP-1 rebound is plausible, but Signos has not yet proven it can solve the problem.
Reimbursement remains early. Signos is targeting self-insured employers—companies that bear their own health cost risk and have direct incentive to offset GLP-1 spending. Traditional health plan coverage is not yet material to the growth model.
What to watch
Monitor whether Signos publishes retention data in the next 12 months. The company is well-funded and has regulatory clearance, but the competitive risk is straightforward: if glucose data alone does not change behavior, Signos becomes a niche tool for the subset of users who find the data intrinsically motivating (similar to fitness trackers). If it does work, employer adoption could be rapid, especially among companies already spending heavily on GLP-1 benefits.
The funding round also signals that the CGM market is bifurcating. Dexcom's leadership in diabetes care is established; Signos' bet is that the non-diabetic, weight-loss segment will support a separate business model and brand. That separation is reasonable, but it depends on behavioral outcomes that have not yet been published.